1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends

KOL Insight: Prostate Cancer: Competition intensifies in race to the top

  • November 2013
  • Firstword Pharma
Report ID: 1163038

Summary

Table of Contents




The Prostate Cancer market has seen a number of progressive changes in recent years. The launches of Johnson & Johnson’s Zytiga (abiraterone acetate) and Medivation/Astellas’s Xtandi (enzalutamide) has reinvigorated the post-chemo treatment segment, while launch of the first cancer vaccine Provenge (sipuleucel-T; Dendreon) and Zytiga’s expanded approval had finally given new options in the pre-chemo setting. With similar efficacy and tolerability profiles, Zytiga and Xtandi are currently vying for first-line status in both the post and pre-chemo disease settings as both drugs are set to generate blockbusting revenues despite clinical and health payer concerns about the high cost of treatment. The recent addition of Xofigo, the first licensed alpha-emitter in prostate cancer, also represents a paradigm shift in treatment.

Competition in the major segments of prostate cancer are set to intensify, with new hormone drugs, radiation therapy, chemotherapy add-ons and immunotherapies in the pipeline. The high level of unmet needs, premium pricing and patient population growth continue to make the market an attractive proposition for ‘would be’ developers. There remains a significant opportunity to generate substantial revenues in this highly-segmented disease, in the therapeutic segment and also in advanced diagnostics.







Key Benefits

Understand the Unique Benefits of KOL Insight: Prostate cancer
Prostate Cancer: Competition intensifies in race to the top examines the most prominent insights gained from the field’s key opinion leaders. The results of FirstWord’s research and analysis will help you to:

Comprehend the current trends driving and shaping the global prostate cancer market
Understand the future landscape and how new classes will fit into the treatment algorithm
Compare and contrast the clinical profile of Johnson & Johnson’s Zytiga and Medivation/Astellas’s Xtandi and assess their competitive strengths and weaknesses
Assess the impact of Xofigo’s arrival onto the market
Assess the commercial and clinical potential of the pipeline hormone drugs, radiation therapy, chemotherapy add-ons and next generation immunotherapy
Appreciate KOL calls for diagnostic biomarkers and understand the commercial threat and opportunity such products present
Evaluate the performance of companies with the most robust new product pipelines


rostate Cancer: Competition intensifies in race to the top answers key questions including:


How will pricing affect Xofigo’s uptake?
How might new therapies impact on current first-line chemo treatments?
What are the current unmet needs and major challenges in prostate cancer treatment?
What are the most promising late-stage classes in development?
How will the new therapies be positioned against each other in each of the disease segments?
In what ways could biomarkers improve future Prostate Cancer disease management and what impact could this have on prescribing?
How do KOLs think the pricing environment is shaping the uptake of new Prostate Cancer treatments?
What clinical research trends do KOLs predict for future Prostate Cancer therapies?



KOL Panel

The Prostate Cancer KOL panel assembled for this Therapy Trends research is drawn from North American and European professionals:

Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus, Boulder, CO, USA
Assistant Professor in Medicine-Hematology/Oncology, Northwestern University Feirnberg School of Medicine, Chicago, IL; Physician in practice, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
Associate Director and Senior-Vice President for Translational Research, Chair, Department of Urology, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY; Professor of Urology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, NY, USA
Professor of Urology and Professor of Oncology and Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine, Baltimore, MA, USA
Director of the Genitourinary Oncology Program at Massachusetts General Hospital Cancer Center, Massachusetts; Associate Professor of Medicine at Harvard Medical School, Boston, MA, USA
Honorary Professor in Urological Cancer/Consultant Urologist, Institute of Cancer Sciences, Christies Cancer Hospital, University of Manchester, UK; Consultant Urological Surgeon, The Christie, Salford Royal NHS Foundation Trust, and Honorary Professor of Urological Oncology, Manchester University, Manchester, UK.
Head of the Department of Cancer Medicine, the Institut Gustave Roussy, Villejuif, and Full Professor in Oncology, the University of Paris, France.
Consultant Clinical Oncologist at The Royal Marsden, London, UK.
Professor of Medical Oncology, Georges Pompidou European Hospital, Paris, France.
Consultant Clinical Oncologist, The Royal Marsden Hospital, Sutton, UK.
Head of Urology Clinic, Viersen General Hospital, Viersen, Germany


Event Assessments
Stay a step ahead with Therapy Trends Event Assessments. Over the next 12 months, you will receive updated qualitative analysis every time a major market event breaks. Updates will be delivered straight into your inbox within days of each event’s occurrence.
Whether it’s a predicted product approval or an unexpected late stage failure, Therapy Trends has the resources and knowledge to keep you up to date with the latest market analysis.



Methodology
This report provides a qualitative overview of the current and future Prostate Cancer market. Information was gathered from telephone discussions held with twelve key opinion leaders (KOLs), from across the major Prostate Cancer markets, including France, Germany, Italy, the UK and the US. These regions were selected because they contain many of the largest global markets for the pharmaceutical industry, and also dictate the dynamics of Pharma markets in other countries.

In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific publications, involvement with Pharma, involvement in clinical trials, and record of presenting at high profile international conferences.
Subject matter for discussion in the interviews covered future diagnostic and therapeutic strategies for Prostate Cancer, the future of Prostate Cancer drug classes, and new drugs entering the market. These leading KOLs also gave their views on current research, the usefulness of existing Prostate Cancer drug classes, the cost of newer drugs and other concerns in the therapy area.



Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Minimally invasive mitral valve repair and replacement procedures. Combined report. European reimbursement report

  • $ 19250
  • Industry report
  • April 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of the reimbursement situation in Europe for all developed or currently under development minimally invasive (transapical approach via mini-thoracotomy) and transcatheter mitral ...

Robotic surgery interventions. European reimbursement report

  • $ 10450
  • Industry report
  • May 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of reimbursement situation for procedures using robotic equipment in European countries. Five the most common robotic surgical procedures are included into report: total prostatectomy ...

Angioplasty of arteries of lower extremities for peripheral artery disease. European reimbursement report

  • $ 10450
  • Industry report
  • April 2017
  • by Med Tech Reimbursement Consulting

Report presents summary of the reimbursement situation in Europe for a group of angioplasty procedures of arteries of lower extremities for peripheral artery disease (plain and drug-eluting balloon angioplasty, ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.